BMS 986141

Drug Profile

BMS 986141

Alternative Names: BMS-986141; UDM-003183

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb; Institute for Research in Immunology and Cancer - Commercialization of Research
  • Class
  • Mechanism of Action PAR-4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Thrombosis

Most Recent Events

  • 02 Feb 2017 Bristol-Myers Squibb withdraws prior to enrolment a phase I pharmacokinetics trial in subjects with hepatic impairment and in healthy volunteers in USA (NCT02985632)
  • 26 Jan 2017 Bristol-Myers Squibb plans a phase I bioavailability trial in Healthy volunteers in USA (PO) (NCT03035734)
  • 29 Dec 2016 Phase-II clinical trials in Thrombosis in Japan (PO) (NCT02671461)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top